Cardiac Involvement Due to COVID-19: Insights from Imaging and Histopathology

Eur Cardiol. 2023 Oct 18:18:e58. doi: 10.15420/ecr.2023.02. eCollection 2023.

Abstract

Lingering cardiac symptoms are increasingly recognised complications of severe acute respiratory syndrome coronavirus 2 infection, now referred to as post-acute cardiovascular sequelae of COVID-19 (PASC). In the acute phase, cardiac injury is driven by cytokine release and stems from ischaemic and thrombotic complications, resulting in myocardial necrosis. Patients with pre-existing cardiac conditions are particularly vulnerable. Myocarditis due to a direct viral infection is rare. Chronic symptoms relate to either worsening of pre-existing heart disease (PASC - cardiovascular disease) or delayed chronic inflammatory condition due to heterogenous immune dysregulation (PASC - cardiovascular syndrome), the latter affecting a broad segment of previously well people. Both PASC presentations are associated with increased cardiovascular risk, long-term disability and reduced quality of life. The recognition and management of PASC in clinical settings remains a considerable challenge. Sensitive diagnostic methods are needed to detect subtler inflammatory changes that underlie the persistent symptoms in PASC - cardiovascular syndrome, alongside considerable clinical experience in inflammatory cardiac conditions.

Keywords: COVID-19; PASC; cardiovascular magnetic resonance; myocardial injury; myocarditis; post-acute sequelae of COVID-19.

Publication types

  • Review

Grants and funding

German Ministry of Education and Research via the German Centre for Cardiovascular Research (DZHK) partner site Rhein-Main to EN, VOP, AR, FE. Deutsche Herzstiftung e.V. Frankfurt am Main, Germany. Cardio-Pulmonary Institute (CPI), EXC 2026, Project ID: 390649896. Bayer AG, Leverkusen, Germany. AS received funding from the European Association of Cardiovascular Imaging (EACVI Research Grant [App000071230]).